Global Rosacea Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Rosacea treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Accuitis, Accuitis Pharmaceuticals Inc, Afecta Pharmaceuticals Inc, Aiviva BioPharma Inc, Alfasigma S.p.A. and others.
A Significant contribution to the Rosacea pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Rosacea pipeline included 20 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Rosacea condition and increased access to investments is encouraging growth of Rosacea drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Rosacea drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Rosacea therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Rosacea pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Rosacea. Further, orphan drug status, fast track designation, grants awarded and other special status for Rosacea pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Rosacea pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Rosacea Pipeline candidates-
A Significant contribution to the Rosacea pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Rosacea pipeline included 20 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Rosacea condition and increased access to investments is encouraging growth of Rosacea drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Rosacea drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Rosacea therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Rosacea pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Rosacea. Further, orphan drug status, fast track designation, grants awarded and other special status for Rosacea pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Rosacea pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Rosacea Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Rosacea drugs
- Late phase: Phase 3 and in-approval Rosacea drugs
- Company overview
- Snapshot
- Rosacea therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Rosacea- Disease Overview
2.2 Rosacea- Pipeline Snapshot
2.3 Rosacea- Pipeline Drugs by Phase
2.4 Rosacea- Pipeline Drugs by Company
2.5 Rosacea- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Accuitis Rosacea Drug Pipeline, H2- 2019
3.2 Accuitis Pharmaceuticals Inc Rosacea Drug Pipeline, H2- 2019
3.3 Afecta Pharmaceuticals Inc Rosacea Drug Pipeline, H2- 2019
3.4 Aiviva BioPharma Inc Rosacea Drug Pipeline, H2- 2019
3.5 Alfasigma S.p.A. Rosacea Drug Pipeline, H2- 2019
3.6 AOBiome LLC Rosacea Drug Pipeline, H2- 2019
3.7 Biomimetix JV LLC Rosacea Drug Pipeline, H2- 2019
3.8 BioPharmX Inc Rosacea Drug Pipeline, H2- 2019
3.9 Cellix Bio Pvt Ltd Rosacea Drug Pipeline, H2- 2019
3.10 Cutanea Life Sciences Inc Rosacea Drug Pipeline, H2- 2019
3.11 Dermata Therapeutics LLC Rosacea Drug Pipeline, H2- 2019
3.12 Emeriti Pharma AB Rosacea Drug Pipeline, H2- 2019
3.13 Foamix Pharmaceuticals Ltd Rosacea Drug Pipeline, H2- 2019
3.14 Hovione Rosacea Drug Pipeline, H2- 2019
3.15 Matrisys Bioscience Inc Rosacea Drug Pipeline, H2- 2019
3.16 PHI Therapeutics Inc Rosacea Drug Pipeline, H2- 2019
3.17 Promius Pharma LLC Rosacea Drug Pipeline, H2- 2019
3.18 Sol-Gel Technologies Ltd Rosacea Drug Pipeline, H2- 2019
3.19 Sunny Pharmtech Inc Rosacea Drug Pipeline, H2- 2019
3.20 TWi Biotechnology Inc Rosacea Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Rosacea- Phase 1 Drug Details
4.2 Rosacea- Phase 1 Drug Overview
4.3 Rosacea- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Rosacea- Phase 2 Drug Details
5.2 Rosacea- Phase 2 Drug Overview
5.3 Rosacea- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Rosacea- Phase 3 Drug Details
6.2 Rosacea- Phase 3 Drug Overview
6.3 Rosacea- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Rosacea- Pre-clinical Phase Drug Details
7.2 Rosacea- Pre-clinical Phase Drug Overview
7.3 Rosacea- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Rosacea- Disease Overview
2.2 Rosacea- Pipeline Snapshot
2.3 Rosacea- Pipeline Drugs by Phase
2.4 Rosacea- Pipeline Drugs by Company
2.5 Rosacea- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Accuitis Rosacea Drug Pipeline, H2- 2019
3.2 Accuitis Pharmaceuticals Inc Rosacea Drug Pipeline, H2- 2019
3.3 Afecta Pharmaceuticals Inc Rosacea Drug Pipeline, H2- 2019
3.4 Aiviva BioPharma Inc Rosacea Drug Pipeline, H2- 2019
3.5 Alfasigma S.p.A. Rosacea Drug Pipeline, H2- 2019
3.6 AOBiome LLC Rosacea Drug Pipeline, H2- 2019
3.7 Biomimetix JV LLC Rosacea Drug Pipeline, H2- 2019
3.8 BioPharmX Inc Rosacea Drug Pipeline, H2- 2019
3.9 Cellix Bio Pvt Ltd Rosacea Drug Pipeline, H2- 2019
3.10 Cutanea Life Sciences Inc Rosacea Drug Pipeline, H2- 2019
3.11 Dermata Therapeutics LLC Rosacea Drug Pipeline, H2- 2019
3.12 Emeriti Pharma AB Rosacea Drug Pipeline, H2- 2019
3.13 Foamix Pharmaceuticals Ltd Rosacea Drug Pipeline, H2- 2019
3.14 Hovione Rosacea Drug Pipeline, H2- 2019
3.15 Matrisys Bioscience Inc Rosacea Drug Pipeline, H2- 2019
3.16 PHI Therapeutics Inc Rosacea Drug Pipeline, H2- 2019
3.17 Promius Pharma LLC Rosacea Drug Pipeline, H2- 2019
3.18 Sol-Gel Technologies Ltd Rosacea Drug Pipeline, H2- 2019
3.19 Sunny Pharmtech Inc Rosacea Drug Pipeline, H2- 2019
3.20 TWi Biotechnology Inc Rosacea Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Rosacea- Phase 1 Drug Details
4.2 Rosacea- Phase 1 Drug Overview
4.3 Rosacea- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Rosacea- Phase 2 Drug Details
5.2 Rosacea- Phase 2 Drug Overview
5.3 Rosacea- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Rosacea- Phase 3 Drug Details
6.2 Rosacea- Phase 3 Drug Overview
6.3 Rosacea- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Rosacea- Pre-clinical Phase Drug Details
7.2 Rosacea- Pre-clinical Phase Drug Overview
7.3 Rosacea- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
